TD Cowen Starts Benitec BioPharma (BNTC) at Buy

TD Cowen analyst Ritu Baral initiates coverage on Benitec BioPharma (NASDAQ: BNTC) with a Buy rating.

The analyst comments "We are initiating on BNTC with a Buy. BNTC's DNA-directed 'Silence and Replace' platform combines RNAi silencing sequences with WT replacement genes. Lead asset BB-301 for OPMD showed compelling 1st Ph1/2 clinical data, improving subjective & objective dysphagia measures in 3pts. We think interim data (f/ 6pts) in 2H25 will likely show even greater benefit, supporting straightforward development."

For an analyst ratings summary and ratings history on Benitec BioPharma click here. For more ratings news on Benitec BioPharma click here.

Shares of Benitec BioPharma closed at $13.17 yesterday.

You May Also Be Interested In

• BofA Securities Downgrades PagSeguro (PAGS) to Neutral
• Mizuho Reiterates Outperform Rating on Ovintiv Inc. (OVV)
• XPeng Inc. (XPEV) Plans To Launch Humanoid Robot Globally Next Year - WSJ